IntelligentMDx designs, develops and commercializes clinically impactful molecular diagnostic test solutions. Our goal is to support clinicians in their efforts to provide care with certainty. Our commercial offerings include emerging and re-emerging infectious threats and are available for use in CLIA laboratories covering the rapidly growing markets for seasonal/pandemic influenza, health care-associated infections and transplantation. IntelligentMDx’s expertise spans evolutionary biology, bioinformatics, and wet lab/molecular biology capabilities, harnessed by our proprietary product development process allowing for the rapid design and development of tests to meet clinical needs.
A privately held company based in Cambridge, MA, IntelligentMDx has been named a Business Leader in Medical Diagnostics by Scientific American magazine within the Scientific American 50. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations is enabling us to be a leader in the high value diagnostic content market.
(
www.intelligentmdx.com )
